Intramyocardial delivery of injectable hydrogel with arctigenin alleviated myocardial ischemia –reperfusion injury in rats

AbstractArctigenin belongs to a major bioactive component ofFructus arctii and has been found with cardioprotective effects on rats with ischemia ‒reperfusion (I/R) injury. The application of arctigenin is limited due to poor water solubility and low bioavailability. Hydrogel drug delivery systems can improve the efficacy and safety of drugs, increase drug utilization, and reduce side effects. We hypothesized that hydrogels containing arcti genin would facilitate the effect of arctigenin and alleviate I/R injury in the rat heart. Presently, adult Sprague–Dawley (SD) rats were subjected to 1 h of I/R injury, then hydrogels comprising arctigenin were implanted into the myocardium of rats. Triphenyl tetrazolium chloride staining, hemat oxylin–eosin staining, and terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling staining and Western blot were performed for evaluating the infarct size, histopathological, and vital protein alterations of hearts. It was discovered that the hydrogel combined with arctigenin abated apoptosis and reduced infarct size. In addition, the results of echocardiography and Masson staining suggested that the hydrogel with arctigenin improved cardiac function, restrained myocardial fibrosis, and activated AMP-activated protein kinase (AMPK) and sirtuin 1 (SIRT1). Collectively, the inje ctable hydrogel delivery system enhances the effect of arctigenin, which may play a protective role in I/R injury by activating AMPK and SIRT1.
Source: Biotechnology and Applied Biochemistry - Category: Biochemistry Authors: Tags: ORIGINAL ARTICLE Source Type: research